Which hedge funds own GSK? GSK PLC, Q2 2026 13F holders
Healthcare · Open on the interactive board
10 of the hedge funds tracked by WhaleCreep disclosed a position in GSK (GSK PLC) in their Q2 2026 13F filings, worth $242.2m in total. The largest holder by portfolio weight is Kahn Brothers at 1.3% of its book. 4 managers opened a new position this quarter: Point72 Asset Management LP, D. E. Shaw & Co, Citadel Advisors, Marshall Wace. 2 exited: Holocene Advisors, Renaissance Technologies LLC.
10tracked managers holding
4opened this quarter
2exited this quarter
Which hedge funds hold GSK? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Kahn Brothers | Q2 2026 | 1.3% | $8.3m | 158,438 | -2% | reduced |
| Tweedy Browne | Q2 2026 | 0.3% | $4.3m | 81,527 | -0% | held |
| Point72 Asset Management LP | Q2 2026 | 0.2% | $139.1m | 2,652,881 | – | new |
| Bridgewater Associates | Q2 2026 | 0.1% | $26.4m | 504,171 | -28% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $53.4m | 1,019,449 | – | new |
| Horizon Kinetics | Q2 2026 | 0.0% | $1.3m | 24,046 | -2% | reduced |
| Citadel Advisors | Q2 2026 | 0.0% | $7.9m | 151,573 | – | new |
| Ancora Advisors | Q2 2026 | 0.0% | $71.4k | 1,362 | -74% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $1.2m | 23,174 | – | new |
| First Manhattan | Q2 2026 | 0.0% | $208.4k | 3,941 | 0% | held |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Holocene Advisors | 3.8% | $304.6m |
| Renaissance Technologies LLC | 0.3% | $17.2m |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Boston Omaha | Q4 2024 | 0.0% |
How has hedge fund ownership of GSK changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $242.2m |
| Q1 2026 | 9 | $375.8m |
| Q4 2025 | 9 | $605.1m |
| Q3 2025 | 8 | $469.0m |
| Q2 2025 | 7 | $383.7m |
| Q1 2025 | 7 | $334.3m |
| Q4 2024 | 9 | $228.7m |
| Q3 2024 | 8 | $145.0m |
| Q2 2024 | 8 | $333.9m |
| Q1 2024 | 10 | $495.7m |
| Q4 2023 | 10 | $4.2bn |
| Q3 2023 | 10 | $4.0bn |
| Q2 2023 | 10 | $239.1m |
| Q1 2023 | 10 | $218.8m |
| Q4 2022 | 7 | $460.7m |
| Q3 2022 | 7 | $415.4m |
Counts every tracked manager that disclosed GSK in that quarter's filing, including managers that have since stopped filing.